Natalia Gonzalez Caldito

Natalia Gonzalez Caldito

Auto-generated profile, based on publicly available information

Natalia Gonzalez Caldito

Department of Neurology, Multiple Sclerosis and Neuroimmunology, Northwestern University, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2020 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ESElias S. Sotirchos
Elias S. Sotirchos
NCNatalia Gonzalez Caldito
Natalia Gonzalez Caldito
AFAngeliki Filippatou
Angeliki Filippatou
KFKathryn C. Fitzgerald
Kathryn C. Fitzgerald
OMOlwen C. Murphy
Olwen C. Murphy
ICInternational Multiple Sclerosis Visual System (IMSVISUAL) Consortium
International Multiple Sclerosis Visual System (IMSVISUAL) Consortium

21 August 2020 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
NCNatalia Gonzalez Caldito
Natalia Gonzalez Caldito
Afsaneh ShiraniAfsaneh Shirani
Afsaneh Shirani
ASAmber Salter
Amber Salter
OSOlaf Stuve
Olaf Stuve
Background: Rituximab and ocrelizumab are anti-CD20 monoclonal antibodies that have shown a marked reduction in multiple sclerosis (MS) inflammatory activity. However, their real-world safety profile has not been adequately compared. Objective: To investigate the adverse event (AE) profile of rituximab and ocrelizumab reported to the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: The FAERS database was filtered by indication (MS) and drug (rituximab or ocrelizumab). Disproportionality analyses including but not limited to reporting odds ratio (ROR) were conducted to identify drug–AE associations. A signal was detected if the lower limit of the 95% confidence interval of ROR (ROR025) exceeded 1. Results: There were 623 and 7948 reports for rituximab and ocrelizumab, respectively. The most frequent AEs with rituximab and ocrelizumab were infusion-related reaction (4.82%) and urinary tract infection (10.52%), respectively. The strongest drug–AE association for rituximab and ocrelizumab were ear pruritus (ROR025: 47.53) and oral herpes (ROR025: 38.99), respectively. Ocrelizumab was associated with an almost two times higher frequency of infections than rituximab (21.93% vs 11.05%, respectively). Conclusion: This study revealed differences in reporting AEs between rituximab and ocrelizumab. Infections were reported more frequently with ocrelizumab. Although speculative, a potentially different or more extensive B-cell depletion by ocrelizumab might explain these findings. Additional pharmacovigilance studies need to be performed to better characterize differences in the AE profile in B-cell-depleting therapies.

23 February 2021 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
NCNatalia Gonzalez Caldito
Natalia Gonzalez Caldito
SOShirley O’lEary
Shirley O’lEary
OSOlaf Stuve
Olaf Stuve
One known adverse event associated with dimethyl fumarate (DMF) is grade III lymphopenia which usually resolves within 2–3 months upon DMF discontinuation. Here, we report a case of a 50-year-old woman with MS who developed grade III lymphopenia within 6 months of DMF initiation, and despite treatment cessation within the next 6 months, she has continued to have severe persistent lymphopenia for over 5 years. Our observation suggests prolonged and possibly irreversible lymphopenia as a possible adverse event of DMF, and it emphasizes the need for monitoring lymphocyte numbers, and to cease dosing promptly after onset of grade III lymphopenia.

24 November 2023 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
NCNatalia Gonzalez Caldito
Natalia Gonzalez Caldito
EGEdith L Graham
Edith L Graham
EGElena Grebenciucova
Elena Grebenciucova
Late-onset neutropenia (LON) is a rare adverse event that has not been reported from in utero exposure. We describe a case of LON in an infant, whose mother had neuromyelitis optica and received rituximab in the third trimester due to re-emergence of CD19 B cells. The newborn was born without complications but 2 months later was found to have grade IV neutropenia. No etiology was identified. Neutropenia self-resolved within 1 week. This case emphasizes an unmet need for developing guidelines and protocols to manage in utero rituximab exposure.

1 January 2020 in Journal of Central Nervous System Disease
Verified
Journal Article
Open access
PDF file
NCNatalia Gonzalez Caldito
Natalia Gonzalez Caldito
JLJ Scott Loeb
J Scott Loeb
DODarin T Okuda
Darin T Okuda
This report aims to enhance the understanding of early longitudinal neuroimaging features of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV). Neuroimaging has become crucial in the diagnosis and early recognition of PML. Recognition of magnetic resonance imaging (MRI) features in the early stages of PML is paramount to avoid misdiagnosis and facilitate the delivery of treatments aimed at reducing disease progression. A 49-year-old white man with HIV presented with 4-month progressive left-sided weakness. Neurological examination revealed mild cognitive impairment, left-sided hemiparesis, and somatosense impairment to all modalities. Brain MRI revealed a punctate pattern with innumerable T2-FLAIR (fluid attenuated inversion recovery) hyperintensities in the cortex, brainstem, cerebellum, subcortical, and periventricular areas. Susceptibility-weighted imaging (SWI) revealed hypointensities involving subcortical U-fibers and cortical architecture. A comprehensive diagnostic evaluation was inconclusive. John Cunningham virus (JCV) PCR in cerebrospinal fluid (CSF) was indeterminate. He was started on antiretroviral therapy. Repeat brain MRI performed 1.5 months later, in the setting of further neurological decline, demonstrated progression of the T2-hyperintensities into a large confluent white matter lesion in the right frontoparietal lobe. Despite an indeterminate JCV PCR, the appearance and characteristic progression of the lesions in successive imaging in the setting of severe immunosuppression, with extensive negative infectious workup, was indicative of PML. This clinical experience illustrates unique neuroimaging features of HIV-PML in early stages and its progression over time. It especially highlights the relevance of the SWI sequence in the diagnosis and features observed with disease evolution. Short-term imaging follow-up may assist with the recognition of MRI features consistent with the biology of the infection.